Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.

Literature DB >> 20811399

JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.

H Andrikovics, S Nahajevszky, M Koszarska, N Meggyesi, A Bors, G Halm, S Lueff, N Lovas, Z Matrai, J Csomor, R Rasonyi, M Egyed, J Varkonyi, G Mikala, A Sipos, A Kozma, E Adam, S Fekete, T Masszi, A Tordai.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2010 PMID： 20811399 DOI： 10.1038/leu.2010.172

Source DB: PubMed Journal: Leukemia ISSN： 0887-6924 Impact factor: 11.528

Keyword Cloud
Cited

× No keyword cloud information.

10 in total

1. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?

Authors: Sylvie Hermouet; Mathias Vilaine
Journal: Haematologica Date: 2011-11 Impact factor: 9.941

2. Inherited predisposition to myeloproliferative neoplasms.

Authors: Amy V Jones; Nicholas C P Cross
Journal: Ther Adv Hematol Date: 2013-08

3. The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.

Authors: Sarolta Nahajevszky; Hajnalka Andrikovics; Arpad Batai; Emma Adam; Andras Bors; Judit Csomor; Laszlo Gopcsa; Magdalena Koszarska; Andras Kozma; Nora Lovas; Sandor Lueff; Zoltan Matrai; Nora Meggyesi; Janos Sinko; Andrea Sipos; Andrea Varkonyi; Sandor Fekete; Attila Tordai; Tamas Masszi
Journal: Haematologica Date: 2011-07-26 Impact factor: 9.941

4. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.

Authors: Xinju Zhang; Tingting Hu; Zhiyuan Wu; Zhihua Kang; Weiwei Liu; Ming Guan
Journal: Int J Hematol Date: 2012-09-29 Impact factor: 2.490

5. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.

Authors: Éva Pósfai; Imelda Marton; Péter Attila Király; Balázs Kotosz; Zsuzsanna Kiss-László; Márta Széll; Zita Borbényi
Journal: Pathol Oncol Res Date: 2015-01-10 Impact factor: 3.201

6. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Authors: Hajnalka Andrikovics; Tunde Krahling; Katalin Balassa; Gabriella Halm; Andras Bors; Magdalena Koszarska; Arpad Batai; Janos Dolgos; Judit Csomor; Miklos Egyed; Andrea Sipos; Peter Remenyi; Attila Tordai; Tamas Masszi
Journal: Haematologica Date: 2014-06-03 Impact factor: 9.941

JAK2 46/1 haplotype analysis in myeloproliferative neoplasms and acute myeloid leukemia.

1. The JAK2 46/1 haplotype: a marker of inappropriate myelomonocytic response to cytokine stimulation, leading to increased risk of inflammation, myeloid neoplasm, and impaired defense against infection?

2. Inherited predisposition to myeloproliferative neoplasms.

3. The prognostic impact of germline 46/1 haplotype of Janus kinase 2 in cytogenetically normal acute myeloid leukemia.

4. The JAK2 46/1 haplotype is a risk factor for myeloproliferative neoplasms in Chinese patients.

5. JAK2 V617F, MPL, and CALR mutations in essential thrombocythaemia and major thrombotic complications: a single-institute retrospective analysis.

6. Distinct clinical characteristics of myeloproliferative neoplasms with calreticulin mutations.

Review 7. Advances in germline predisposition to acute leukaemias and myeloid neoplasms.

8. The role of genotypes that modify the toxicity of chemical mutagens in the risk for myeloproliferative neoplasms.

9. Association between JAK2 rs4495487 Polymorphism and Risk of Budd-Chiari Syndrome in China.

Review 10. The JAK2 GGCC (46/1) Haplotype in Myeloproliferative Neoplasms: Causal or Random?